Pioglitazone and Glimepiride Tablets
Generic name: pioglitazone hydrochloride and glimepiride
Dosage form: tablet
Drug class:Antidiabetic combinations
Medically reviewed by Drugs.com. Last updated on Dec 1, 2021.
On This Page
- Boxed Warning
- Indications and Usage
- Dosage and Administration
- Dosage Forms and Strengths
- Contraindications
- Warnings and Precautions
- Adverse Reactions/Side Effects
- Drug Interactions
- Use In Specific Populations
- Overdosage
- Description
- Clinical Pharmacology
- Nonclinical Toxicology
- Clinical Studies
- How Supplied/Storage and Handling
- Patient Counseling Information
- Medication Guide
WARNING: CONGESTIVE HEART FAILURE
- Thiazolidinediones, including pioglitazone, which is a component of Pioglitazone and Glimepiride Tablets, cause or exacerbate congestive heart failure in some patients [see Warnings and Precautions (5.1)].
- After initiation of Pioglitazone and Glimepiride Tablets and after dose increases, monitor patients carefully for signs and symptoms of heart failure (e.g., excessive, rapid weight gain, dyspnea, and/or edema). If heart failure develops, it should be managed according to current standards of care and discontinuation or dose reduction of Pioglitazone and Glimepiride Tablets must be considered [see Warnings and Precautions (5.1)].
- Pioglitazone and Glimepiride Tablets are not recommended in patients with symptomatic heart failure [see Warnings and Precautions (5.1)].
- Initiation of Pioglitazone and Glimepiride Tablets in patients with established New York Heart Association (NYHA) Class III or IV heart failure is contraindicated [see Contraindications (4) and Warnings and Precautions (5.1)].
Indications and Usage for Pioglitazone and Glimepiride Tablets
Pioglitazone and Glimepiride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulf...
